About Us
Our vision... is to be the global leaders in prescription cannabinoid medicines, through the rapid cost-effective development of pharmaceutical products which address clear unmet patient needs.
GW is developing a portfolio of cannabinoid medicines, of which the lead product is Sativex, an oromucosal spray for the treatment of MS symptoms, cancer pain and neuropathic pain.
GW Pharmaceuticals was founded in 1998 and its shares are listed on AIM, a market of the London Stock Exchange. The company is developing a product portfolio of cannabinoid prescription medicines, including Sativex. GW occupies a world-leading position in cannabinoid science....read more.Overview
GW’s focus is to develop novel prescription medicines which make a real difference to the lives of patients.
